Long Term Follow Up: Phase I Trial of

Awards Nomination 20+ Million Readerbase

Research Article - (2013) Volume 4, Issue 8

Neil Senzer^1,^2,^3,⁴, Minal Barve³, Jacklyn Nemunaitis¹, Joseph Kuhn⁵, Anton Melnyk⁶, Peter Beitsch⁴, Mitchell Magee⁷, Jonathan Oh³, Cynthia Bedell¹, Padmasini Kumar², Donald D Rao², Beena O Pappen², Gladice Wallraven², Charles Brunicardi F⁸, Phillip B Maples² and John Nemunaitis^1,^2,^3,⁴^*: ¹Mary Crowley Cancer Research Centers, Dallas, TX, USA, E-mail: neilsenzer@gmail.com; ²Gradalis, Inc., Dallas, TX, USA, E-mail: neilsenzer@gmail.com; ³Texas Oncology, P.A., Dallas, TX, USA, E-mail: neilsenzer@gmail.com; ⁴Medical City Dallas Hospital, Dallas, TX, USA, E-mail: neilsenzer@gmail.com; ⁵WLS Surgical Associates, P.A., Dallas, TX, USA, E-mail: neilsenzer@gmail.com; ⁶Texas Cancer Center, Abilene, TX, USA, E-mail: neilsenzer@gmail.com; ⁷Cardiovascular Specialty Associates of North Texas, P.A., Dallas, TX, USA, E-mail: neilsenzer@gmail.com; ⁸Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA, E-mail: neilsenzer@gmail.com

^*Corresponding Author: